PRODUCT LICENSE AND COLLABORATION AGREEMENTProduct License and Collaboration Agreement • February 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories
This Product License and Collaboration Agreement (this “Agreement”) is made and entered into as of this 4 day of May, 2007 (the “Effective Date”), by and between (i) BG Medicine, Inc., a Delaware corporation (“BGM”), (ii) ACS Biomarker B.V. i.o. (“ACSB”), a corporation to be established by the University of Maastricht (the “University”), BioMedbooster B.V., a corporation organized under the laws of The Netherlands (“BioMedbooster”), Yigal Pinto, Mat Daemen, Tilman Hackeng and Marcel Kannekens, and (iii) solely for purposes of Section 3.04 hereof, the University and BioMedbooster.
FIRST LOAN MODIFICATION AGREEMENTFirst Loan Modification Agreement • February 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories • California
This First Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of March 28, 2008, by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at One Newton Executive Park, Suite 200, 2221 Washington Street, Newton, Massachusetts 02462 (“Bank”) and BG MEDICINE, INC., a Delaware corporation with its chief executive office located at 610 Lincoln Street, Waltham, Massachusetts 02451.
CONFIDENTIAL GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENTGalectin-3 License and Distribution Agreement • February 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories • Delaware
This GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENT (this “Agreement”), entered into as of November 11, 2009 (the “Effective Date”), by and between Abbott Laboratories, a corporation of the state of Illinois, having its principal place of business at 100 Abbott Park Road, Abbott Park, IL 60064-3500 (“Abbott”) and BG Medicine, Inc., a corporation of the state of Delaware, having its principal place of business at 610 Lincoln Street North Waltham, MA 02451 (“BGM”).
THIRD LOAN MODIFICATION AGREEMENTThird Loan Modification Agreement • February 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories
This Third Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of November 26, 2008, by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at One Newton Executive Park, Suite 200, 2221 Washington Street, Newton, Massachusetts 02462 (“Bank”) and BG MEDICINE, INC., a Delaware corporation with its chief executive office located at 610 Lincoln Street, Waltham, Massachusetts 02451.
SECOND LOAN MODIFICATION AGREEMENTSecond Loan Modification Agreement • February 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories
This Second Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of June 30, 2008, by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at One Newton Executive Park, Suite 200, 2221 Washington Street, Newton, Massachusetts 02462 (“Bank”) and BG MEDICINE, INC., a Delaware corporation with its chief executive office located at 610 Lincoln Street, Waltham, Massachusetts 02451.
STRATEGIC AGREEMENTStrategic Agreement • February 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories • Florida
This Strategic Agreement (“Agreement”) is made and entered into effective as of the 25 day of May, 2007 (“Effective Date”) by and between HUMANA INC. (“Humana”), a Delaware corporation, and BG MEDICINE, INC. (“BGM”), a Delaware corporation. Humana and BGM may be individually referred to herein to as a “Party” and collectively as the “Parties.”
